Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 13, 2010

GSK Taps Activiomics to Research Inflammatory Signaling Mechanisms

  • GlaxoSmithKline has signed on Activiomics to investigate inflammatory signaling mechanisms. The firm was spun out of Barts and The London School of Medicine and Dentistry at Queen Mary University of London based on the development of a mass spectrometry method to analyze and interpret cell-signaling pathways.

    The deal, which marks the first commercial agreement for Activiomics, was inked through GSK’s Respiratory Centre of Excellence for Drug Discovery. Activiomics reports that its Tiquas (targeted in-depth quantification of cell signaling) is quantitative, antibody-free, label-free, and applicable to any cell or tissue sample. This is of significant benefit in the drug development cycle, aiding clinical trial candidate selection and biomarker discovery, thereby reducing development times.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »